QPPV.COM KNOWLEDGE ASSESSMENT

Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making

Test your understanding of the concepts covered by Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A referral concerns a serious safety disagreement. Which conclusion is most accurate?

It is necessarily a pharmacovigilance referral assessed by PRAC It remains an Article 29(4) referral because its legal identity is determined by its MRP or DCP origin It must be reclassified as an Article 107i procedure It cannot be handled under Article 29(4) because that provision only covers efficacy

Question 2 of 10 Which distinction between evidence, rapporteur assessment and CHMP opinion is most appropriate?

They are interchangeable descriptions of the applicant's position The evidence is the underlying information, the rapporteur assessment interprets it scientifically, and the CHMP opinion is the committee's adopted conclusion The rapporteur assessment is legally binding and the CHMP opinion is advisory to the applicant The CHMP opinion contains only raw data and no regulatory conclusion

Question 3 of 10 Which combination best describes the defining prerequisites for an Article 29(4) referral?

A safety signal identified by PRAC involving a centrally authorised medicine An unresolved disagreement during an MRP or DCP based on a potential serious risk to public health Divergent national decisions concerning an already authorised medicinal product An urgent pharmacovigilance concern involving a nationally authorised medicine

Question 4 of 10 Which chronology most accurately represents the core Article 29(4) pathway?

PRAC signal assessment, Commission decision, CMS review, CHMP opinion MRP or DCP, RMS assessment, CMS concern, CMDh coordination, RMS referral, CHMP assessment, Commission decision Commission decision, RMS assessment, CMDh coordination, DCP, national implementation EMA safety investigation, PRAC opinion, RMS referral, national authorisation

Question 5 of 10 What is the correct relationship between an Article 29(4) referral and an internal signal-management process?

The referral automatically proves that a validated safety signal exists The referral and signal-management records should be linked where relevant but remain conceptually distinct The referral replaces the need for signal validation A signal can never be relevant to an Article 29(4) referral

Question 6 of 10 Which implementation activity is most directly required after a Commission decision changes safety wording for nationally authorised products?

Wait for a new PRAC referral before changing national product information Implement the final wording and associated requirements through the applicable national-authorisation framework, with controlled translation and documentation Replace the Commission decision with the company's preferred wording Update only the global safety database and take no regulatory action

Question 7 of 10 Which statement correctly describes the relationship between the original MRP or DCP dossier and the Article 29(4) assessment?

The referral is a completely new marketing authorisation application submitted to EMA The original assessment is irrelevant once CHMP becomes involved The referral escalates an existing disagreement, with the original assessment and referral documentation forming part of the evidentiary history Only information generated after the referral may be considered

Question 8 of 10 What is the key operational distinction between the initial 15-day re-examination notification and the 60-day detailed grounds?

The first is the formal intention to seek re-examination; the second explains the substantive grounds for challenging the opinion The first contains new data; the second is only an administrative acknowledgement The first is submitted to the Commission; the second is submitted to CMDh The first applies only to safety issues; the second applies only to efficacy issues

Question 9 of 10 If Member States reach agreement during CMDh coordination on a qualifying disagreement, what normally follows?

The matter proceeds automatically to CHMP The matter is converted into an Article 31 referral The agreed position is implemented within the MRP or DCP framework The European Commission issues a binding decision without further assessment

Question 10 of 10 Which document establishes the legally binding Union outcome of the referral?

The CMS objection The rapporteur assessment report The CHMP opinion The European Commission decision

Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making

Cookie Settings